Breaking News

Sanofi Licenses Ligand’s Captisol Technology

Will use Captisol in the development and commercialization of cancer therapy SAR-125844

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticals Inc. has entered into a global license and supply agreement with Sanofi to use Captisol in the development and commercialization of SAR-125844, a potent MET kinase inhibitor inPhase Idevelopment in advanced/refractory solid tumors.   Ligand will be eligible to receive potential milestone payments, royalties on sales and revenue from Captisol material sales. Sanofi will be responsible for all costs related to the program.   “This represents the progression and expansion...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters